Nivolumab Reference: HY-P9903 Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
Apitegromab Reference: HY-P99441 Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy.
Bapineuzumab Reference: HY-P99185 Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD).
Sirexatamab Reference: HY-P99906 Sirexatamab is an active peptide. Sirexatamab can be used for various biochemical studies.
Eftilagimod alfa Reference: HY-P99933 Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research.
Immature B Cell Marker Antibody Panel (CD19, CD20, CD22, IgM Fc) (FACS) Reference: ARG30308 Immature B Cell Marker antibody; CD19 antibody; CD20 antibody; CD22 antibody
Camoteskimab Reference: HY-P99491 Camoteskimab (AVTX-007) is a fully human, high-affinity anti-IL-18 monoclonal antibody. Camoteskimab has the potential for the autoinflammatory diseases research, including adult-onset Still’s disease (AOSD).